Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease

Summers, Robert W.; Elliott, David E.; Qadir, Khurram; Urban Jr., Joseph F.; Thompson, Robin; Weinstock, Joel V.
September 2003
American Journal of Gastroenterology;Sep2003, Vol. 98 Issue 9, p2034
Academic Journal
: ObjectivesInflammatory bowel disease (IBD), especially Crohn''s disease (CD), probably results from failure to downregulate a chronic Th1 intestinal inflammatory process. Induction of a Th2 immune response by intestinal helminths diminishes Th1 responsiveness. This study evaluates the safety and effectiveness of helminthic ova in the treatment of active IBD.: MethodsWe studied four patients with active CD and three with ulcerative colitis (UC). In an initial treatment and observation period, a single dose of 2500 live Trichuris suis eggs was given orally, and patients were followed every 2 wk for 12 wk. Baseline medications were continued at the same dose throughout the study. Safety was monitored by following the patients'' clinical status and laboratory studies at regular intervals. Patients also were monitored regularly using the Crohn''s Disease Activity Index, Simple Clinical Colitis Activity Index (SCCAI), and the Inflammatory Bowel Disease Quality of Life Index (IBDQ). To assess safety and efficacy with repetitive doses, two patients with CD and two with UC were given 2500 ova at 3-wk intervals as maintenance treatment using the same evaluation parameters.: ResultsDuring the treatment and observation period, all patients improved clinically without any adverse clinical events or laboratory abnormalities. Three of the four patients with CD entered remission according to the Crohn''s Disease Activity Index; the fourth patient experienced a clinical response (reduction of 151) but did not achieve remission. Patients with UC experienced a reduction of the Clinical Colitis Activity Index to 57% of baseline. According to the IBD Quality of Life Index, six of seven patients (86%) achieved remission. The benefit derived from the initial dose was temporary. In the maintenance period, multiple doses again caused no adverse effects and sustained clinical improvement in all patients treated every 3 wk for >28 wk.: ConclusionsThis open trial demonstrates that it is safe to administer eggs from the porcine whipworm, Trichuris suis, to patients with CD and UC. It also demonstrates improvement in the common clinical indices used to describe disease activity. The benefit was temporary in some patients with a single dose, but it could be prolonged with maintenance therapy every 3 wk. The study suggests that it is possible to downregulate aberrant intestinal inflammation in humans with helminths.


Related Articles

  • Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohn's Disease. Reimund, Jean-Marie; Ratajczyk, Julia; Sola, Brigitte; Justum, Anne-Marie; Muller, Christian D. // Recent Patents on Inflammation & Allergy Drug Discovery;Feb2007, Vol. 1 Issue 1, p21 

    Crohn's disease is a complex multifactorial disorder characterized by the alternation of a cytokine-driven Tlymphocyte-depending inflammation of the intestinal mucosa, and "off" periods, where patients are completely asymptomatic. Although all the causative factors have not been clearly...

  • Viagra for the gut.  // New Scientist;3/4/2006, Vol. 189 Issue 2541, p19 

    This article reports that according to a new study, Viagra can help treat Crohn's disease. A team from University College, London, England, carried out biopsies on six Crohn's disease patients and nine healthy volunteers. The operation triggered an acute immune response in the healthy people,...

  • Evolving paradigms in the pathogenesis of IBD. Mayer, Lloyd // Journal of Gastroenterology;Jan2010, Vol. 45 Issue 1, p9 

    The pathogenesis of all immune-mediated inflammatory diseases has been carefully studied over the past several decades, but it is only recently that we have come to appreciate common pathways and genes. This is especially true for the inflammatory bowel diseases (IBD) Crohn’s disease and...

  • The forgotten role of lymphangitis in Crohn's disease. Kruiningen, H J Van; Colombel, Jean-Frédéric // Gut;Jan2008, Vol. 57 Issue 1, p1 

    Research into Crohn's disease has recently been focused on the genetics of the patient, the gastrointestinal flora, the gut epithelium and mucosal immune responses. For over 60 years pathologists have reported that the fundamental alteration in Crohn's disease occurs in regional lymphatics of...

  • Crohn's Disease and Intestinal Bacteria. Klotter, Jule // Townsend Letter;Jun2013, Issue 359, p20 

    The article reports on the connection between potentially disease-causing bacteria called pathobionts and Crohn's disease (CD). According to Dutch researcher Hermie J. M. Harmsen and colleagues, people with CD experience chronic gut inflammation because of a heightened immune response to...

  • Cytokine Therapies in Crohn's Disease: Where are We Now and where should We Go? Caprioli, Flavio; Pallone, Francesco; Monteleone, Giovanni // Inflammation & Allergy - Drug Targets;Feb2011, Vol. 10 Issue 1, p47 

    No abstract available.

  • Signaling Pathways Associated with Inflammatory Bowel Disease. Wei, Jia; Feng, Jiexiong // Recent Patents on Inflammation & Allergy Drug Discovery;Jun2010, Vol. 4 Issue 2, p105 

    Inflammatory bowel disease (IBD) consists of Crohn's disease (CD) and ulcerative colitis (UC). It is thought to be caused by genetic, abnormal immune response of the intestinal immune system and dysfunction of intestinal mucosal barrier against enteric bacteria. Mutational genes can affect the...

  • Nutrigenomika/nutrigenetyka w leczeniu nieswoistych zapalen jelit. Sadakierska-Chudy, Anna // Gastroenterologia Polska / Gastroenterology;2010, Vol. 17 Issue 1, p53 

    Nutrigenomics/nutrigenetics is a developing field that deals with the interplay between the genome, gene polymorphisms, and dietary components. The pathogenesis of inflammatory bowel disease (IBD) may result in part from genetic polymorphisms that regulate innate and adaptive immune responses as...

  • Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease. Gordon, J. N.; MacDonald, T. T. // Gut;Sep2005, Vol. 54 Issue 9, p1213 

    Presents the author's comments on the role of osteopontin in Crohn's disease. Causes of Crohn's disease; Information on cytokines involved in Crohn's disease; Functions of osteopontin in the body; Importance of plasma cells in inflammatory bowel disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics